Kaleido Biosciences Stock Current Valuation
Valuation analysis of Kaleido Biosciences helps investors to measure Kaleido Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Kaleido Biosciences Company Current Valuation Analysis
Kaleido Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Kaleido Biosciences Current Valuation | (16.73 M) |
Most of Kaleido Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kaleido Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Kaleido Biosciences has a Current Valuation of (16.73 Million). This is 100.12% lower than that of the Pharmaceuticals sector and 100.36% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.1% higher than that of the company.
Kaleido Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaleido Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kaleido Biosciences could also be used in its relative valuation, which is a method of valuing Kaleido Biosciences by comparing valuation metrics of similar companies.Kaleido Biosciences is currently under evaluation in current valuation category among its peers.
Kaleido Fundamentals
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 1.1 M | ||||
| Gross Profit | (66.7 M) | ||||
| EBITDA | (85.09 M) | ||||
| Net Income | (90.29 M) | ||||
| Cash And Equivalents | 38.47 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 5.55 M | ||||
| Debt To Equity | 2.04 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (77.09 M) | ||||
| Short Ratio | 29.34 X | ||||
| Earnings Per Share | (2.16) X | ||||
| Target Price | 22.0 | ||||
| Number Of Employees | 76 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 421.96 K | ||||
| Total Asset | 50.14 M | ||||
| Retained Earnings | (197.63 M) | ||||
| Working Capital | 62.54 M | ||||
| Current Asset | 72.93 M | ||||
| Current Liabilities | 10.39 M | ||||
| Z Score | -6.3 | ||||
| Net Asset | 50.14 M |
Pair Trading with Kaleido Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kaleido Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kaleido Biosciences will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Textron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Textron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Textron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Textron to buy it.
The correlation of Textron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Textron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Textron moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Textron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance |